FOLFIRI with cetuximab or bevacizumab: FIRE-3

Lancet Oncol. 2014 Dec;15(13):e581. doi: 10.1016/S1470-2045(14)70397-3. Epub 2014 Nov 24.

Authors

Filippo Pietrantonio¹, Roberto Iacovelli², Maria Di Bartolomeo², Filippo de Braud²

Affiliations

¹ Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy. Electronic address: filippo.pietrantonio@istitutotumori.mi.it.
² Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.

PMID: 25456372
DOI: 10.1016/S1470-2045(14)70397-3

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Camptothecin / analogs & derivatives*
Colorectal Neoplasms / drug therapy*
Colorectal Neoplasms / pathology*
Female
Humans
Male

Substances

Antibodies, Monoclonal, Humanized
Camptothecin